Can we develop effective combination antiangiogenic therapy for patients with hepatocellular carcinoma?

• Main Authors: Justin B. Wenger (Author), Napoleon Santos (Author), Yanxia Liu (Author), Jennifer Dallas (Author), Sukanthini Subbiah (Author), Steven Hochwald (Author), Emina H. Huang (Author), Long H. Dang (Author), Carmen J. Allegra (Author), Hendrik Luesch (Author), Duyen T. Dang (Author)
• Format: Book
• Published: Frontiers Media S.A., 2011-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Antiangiogenic therapy has shown promise in the treatment of patients with hepatocellular carcinoma (HCC). Bevacizumab, sorafenib, and sunitinib showed efficacy in patients with HCC; and sorafenib is approved by the FDA for treatment of this cancer. In practice, the clinical benefit of these agents...